Pleural effusion in lung cancer: more questions than answers.

Abstract excerpt

Lung cancer remains the most common fatal malignancy, despite more aggressive therapies. Few patients will survive 5 years, as up to 80% of the patients will present with advanced-stage disease at diagnosis. Chemotherapy offers little benefit in terms of median survival and disease-free survival in patients with advanced-stage non-small-cell lung carcinoma (NSCLC). In the last decade, the development of new...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis Inhibitors
• Share to Cyclooxygenase 2
• Share to Cyclooxygenase 2 Inhibitors